Home > Products > HBV-rAAV

HBV Genotype-AAV

HBV infection is species-specific with narrow host range. The most effective choice for animal model of HBV infection is chimpanzee. While chimpanzees are endangered animals with limited sources. Tree shrews can naturally infect human HBV, but there are shortcomings including the infection rate, infection maintenance time, stability and repeatability, resulting in a lack of comparability and repeatability of experimental results.

Therefore, mice with a uniform genetic background remain the best choice for researchers to conduct HBV research. The rAAV virus vector carry 1.3×HBV full-length genome, and the mouse model of persistent HBV infection is prepared by one-time tail vein injection. Such method shows advantages include simple preparation, high success rate, uniformity and stability, obvious dose-effect relationship, and wide application range. HBV-AAV has been widely used in HBV drug evaluation and vaccine screening.

PackGene finished products – quick delivery for your research.   Order product now.

This animal model can greatly shorten the preparation time for the preclinical animal experiment stage of hepatitis B drug research and development with a rather low cost, which can greatly accelerate the progress of hepatitis B treatment programs and new drug research. The AAV-HBV viral vector provided by PackGene Biotech share the significant advantages of good safety, long-term transduction, fast HBV modeling, and stable expression of hepatitis B antigen.

Features of HBV rAAV vector

Highest security

Compared with Lentivirus and Adenovirus, rAAV shows outstanding safety advantages such as extremely low probability of genome integration, extremely low immunogenicity, and high experimental operation safety.

Long-term transduction

In the past 20 years, rAAV has been used as a vector for efficient and long-term gene expression in basic research and clinical gene therapy. According to existing records, its expression in primate muscles can last for more than 10 years.

Organ Specificity

The capsid proteins of different serotypes of AAV recognize different receptors on the cell surface, so the infection efficiency of cells vary in different tissues , showing a certain organ targeting specificity. Among them, AAV8 is the strongest hepatotropic type among AAV vectors and is often used in liver related research.

Our Advantages

  • High purity titer ≥1E+13GC/ml shown in terms of AAV8-based qPCR genome copies/ml
  • Low endotoxin lower than 10EU/ml, suitable for animal experiments.
  • AAV-HBV Mycoplasma test negative.
  • Low empty shell: AAV-HBV TEM detects empty shell rate is below 30%.
  • Complete quality inspection reports are provided.

AAV Type

AAV8-HBV-001
AAV8-HBV-002
AAV8-HBV-003
AAV8-HBV-004

Genotype

HBV-D genotype, AYW genotype
HBV-C genotype, ADR genotype
HBV-C2, replication defective
HBV-B genotype, ADW genotype

Vector

HBV-D-AYW 1.3
HBV-C-ADR 1.3
HBV-C-YMHA-1.3
HBV-B-Adw 1.3

Remark

Epidemic worldwide and in part of China
Mainly epidemic in Asia and China with strong pathogenicity
Epidemic in Asia
Mainly epidemic in Asia and China with less pathogenicity compared with HBV-C type

AAV Type: AAV8-HBV-0001
Genotype: HBV-D genotype, AYW genotype
Vector: HBV-D-AYW 1.3
Remark: Epidemic worldwide and in part of China

AAV Type: AAV8-HBV-0002
Genotype: HBV-C genotype, ADR genotype
Vector: HBV-C-ADR 1.3
Remark:Mainly epidemic in Asia and China with strong pathogenicity

AAV Type: AAV8-HBV-0003
Genotype:  HBV-C2, replication defective
Vector: HBV-C-YMHA-1.3
Remark: Epidemic in Asia

AAV Type: AAV8-HBV-0001
Genotype: HBV-B genotype, ADW genotype
Vector: HBV-B-Adw 1.3
Remark: Mainly epidemic in Asia and China with less pathogenicity compared with HBV-C type

50ul and 100ul specification are available.

Operation Requirements

In 1994,the safety of rAAV as a gene therapy vector was recognized by the FDA. Biological safety is Grade 1 (BSL-1), which is the same as that of plasmid DNA. It is recommended to apply experiments with BSL-2 laboratory and ClassⅡ biological safety cabinet.

Storage Requirements

  • Store the virus at -80°C, take it out when needed, and place it on ice during operation. Product must be used within 24 hours.
  • Calculate the usage in advance, and PackGene will sub-pack the virus  according to the predetermined requirements before shipping to avoid re-freezing and thawing sub-packaging after receiving the goods, which might affect the titer accuracy. If sub-packaging is required, it is recommended to use PCR tubes with siliconized inner wall, or special virus preservation tubes with low protein binding rate.
  • Melt the virus in an ice bath and dilute with PBS or PBS / 0.001% F-68, if you need to dilute the AAV-HBV.

Liver Infection

rAAV has been widely used in animal experiments and cell research. However, please note that, for in vivo experiments, the solutions are various to problems like how to choose the injection site, how much virus to inject, and when to test after injection. It is difficult to have a simple and universal injection solution because of different research fields and animals. It needs to be explored in the experiment.

Design of AAV-HBV Mouse Modeling

Due to individual differences and various operator techniques in model mice, it is strongly recommended that AAV-HBV injection be tested in a gradient of 3 to 4 volumes before the formal experiment, with each injection increasing according to the minimum requirements. For example: a total three serial dilutions: 1E+11GC; 2E+11GC; 3E+11GC.

Product Ordering

SKU Product Description Price Lead Time Quantity Action
AAV-HBV-001-50 AAV8 [HBV-D,ayw],≥1E+13 GC/mL,50ul
AAV-HBV-001-100 AAV8 [HBV-D,ayw],≥1E+13 GC/mL,100ul
AAV-HBV-001-500 AAV8 [HBV-D,ayw],≥1E+13 GC/mL,500ul
AAV-HBV-002-50 AAV8 [HBV-C,adr],≥1E+13 GC/mL,50ul
AAV-HBV-002-100 AAV8 [HBV-C,adr],≥1E+13 GC/mL,100ul
AAV-HBV-002-500 AAV8 [HBV-C,adr],≥1E+13 GC/mL,500ul
AAV-HBV-003-50 AAV8 [HBV-C, Replication Defective],≥1E+13 GC/mL,50ul
AAV-HBV-003-100 AAV8 [HBV-C, Replication Defective],≥1E+13 GC/mL,100ul
AAV-HBV-003-500 AAV8 [HBV-C, Replication Defective],≥1E+13 GC/mL,500ul
AAV-HBV-004-50 AAV8 [HBV-B, adw],≥1E+13 GC/mL,50ul